These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 10642769)
1. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Ali A; Patil S; Grady KJ; Schreiber TL Catheter Cardiovasc Interv; 2000 Feb; 49(2):181-4. PubMed ID: 10642769 [TBL] [Abstract][Full Text] [Related]
2. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related]
3. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768 [TBL] [Abstract][Full Text] [Related]
4. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843 [TBL] [Abstract][Full Text] [Related]
6. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720 [TBL] [Abstract][Full Text] [Related]
9. Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. Iskandar SB; Kasasbeh ES; Mechleb BK; Garcia I; Jackson A; Fahrig S; Albalbissi K; Henry PD J Interv Cardiol; 2006 Aug; 19(4):356-63. PubMed ID: 16881986 [TBL] [Abstract][Full Text] [Related]
10. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy. Wu KK; Willerson JT Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717 [No Abstract] [Full Text] [Related]
11. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ; Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351 [TBL] [Abstract][Full Text] [Related]
12. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219 [TBL] [Abstract][Full Text] [Related]
14. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Bhatt DL; Topol EJ JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650 [TBL] [Abstract][Full Text] [Related]
15. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH; J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451 [No Abstract] [Full Text] [Related]
16. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors. Dunn A Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344 [No Abstract] [Full Text] [Related]
17. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
18. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
19. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953 [No Abstract] [Full Text] [Related]
20. Alveolar hemorrhage as a complication of treatment with abciximab. Kalra S; Bell MR; Rihal CS Chest; 2001 Jul; 120(1):126-31. PubMed ID: 11451827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]